An analysis of C.difficile environmental contamination during and following treatment for C.difficile infection
Background Lower C. difficile spore counts in faeces from C. difficile infection (CDI) patients treated with fidaxomicin vs vancomycin have been observed. We aimed to determine if environmental contamination is lower in patients treated with fidaxomicin compared with those treated with vancomycin/me...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Oxford University Press
2020
|
| _version_ | 1826286248791113728 |
|---|---|
| author | Davies, K Mawer, D Walker, AS Berry, C Planche, T Stanley, P Goldenberg, S Sandoe, J Wilcox, MH |
| author_facet | Davies, K Mawer, D Walker, AS Berry, C Planche, T Stanley, P Goldenberg, S Sandoe, J Wilcox, MH |
| author_sort | Davies, K |
| collection | OXFORD |
| description | Background
Lower C. difficile spore counts in faeces from C. difficile infection (CDI) patients treated with fidaxomicin vs vancomycin have been observed. We aimed to determine if environmental contamination is lower in patients treated with fidaxomicin compared with those treated with vancomycin/metronidazole.
Methods
CDI cases were recruited at four UK hospitals (Leeds, Bradford, Londonx2). Environmental samples (five room sites) were taken pre-treatment, and at 2-3, 4-5, 6-8 and 9-12 days of treatment, end of treatment (EOT), and post-EOT. Faecal samples were collected at diagnosis and as often as produced thereafter. Swabs/ faeces were cultured for C. difficile; percentage of C. difficile positive samples and C. difficile bioburden were compared between different treatment arms at each time-point.
Results
Pre-EOT (n=244) there was a significant reduction in environmental contamination (≥ one site positive) around fidaxomicin vs vancomycin/metronidazole recipients at days 4-5 (30% vs 50% recipients, p=0.04), and at days 9-12 (22% vs 49%, p=0.005). This trend was consistently seen at all other timepoints, but was not statistically significant. No differences were seen between treatment groups post-EOT (n=76). Fidaxomicin-associated faecal positivity rates and colony counts were consistently lower than those for vancomycin/metronidazole from days 4-5 of treatment (including post-EOT); however, the only significant difference was in positivity rate at days 9-12 (15% vs 55%, p=0.03).
Conclusions
There were significant reductions in C. difficile recovery from both faeces and the environment around fidaxomicin vs vancomycin/metronidazole recipients. Fidaxomicin treatment may therefore lower the C. difficile transmission risk by reducing excretion and environmental contamination.
|
| first_indexed | 2024-03-07T01:40:57Z |
| format | Journal article |
| id | oxford-uuid:96d21e6e-0cb1-4c01-99c9-356aed39cff6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:40:57Z |
| publishDate | 2020 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:96d21e6e-0cb1-4c01-99c9-356aed39cff62022-03-26T23:55:38ZAn analysis of C.difficile environmental contamination during and following treatment for C.difficile infectionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:96d21e6e-0cb1-4c01-99c9-356aed39cff6EnglishSymplectic ElementsOxford University Press2020Davies, KMawer, DWalker, ASBerry, CPlanche, TStanley, PGoldenberg, SSandoe, JWilcox, MHBackground Lower C. difficile spore counts in faeces from C. difficile infection (CDI) patients treated with fidaxomicin vs vancomycin have been observed. We aimed to determine if environmental contamination is lower in patients treated with fidaxomicin compared with those treated with vancomycin/metronidazole. Methods CDI cases were recruited at four UK hospitals (Leeds, Bradford, Londonx2). Environmental samples (five room sites) were taken pre-treatment, and at 2-3, 4-5, 6-8 and 9-12 days of treatment, end of treatment (EOT), and post-EOT. Faecal samples were collected at diagnosis and as often as produced thereafter. Swabs/ faeces were cultured for C. difficile; percentage of C. difficile positive samples and C. difficile bioburden were compared between different treatment arms at each time-point. Results Pre-EOT (n=244) there was a significant reduction in environmental contamination (≥ one site positive) around fidaxomicin vs vancomycin/metronidazole recipients at days 4-5 (30% vs 50% recipients, p=0.04), and at days 9-12 (22% vs 49%, p=0.005). This trend was consistently seen at all other timepoints, but was not statistically significant. No differences were seen between treatment groups post-EOT (n=76). Fidaxomicin-associated faecal positivity rates and colony counts were consistently lower than those for vancomycin/metronidazole from days 4-5 of treatment (including post-EOT); however, the only significant difference was in positivity rate at days 9-12 (15% vs 55%, p=0.03). Conclusions There were significant reductions in C. difficile recovery from both faeces and the environment around fidaxomicin vs vancomycin/metronidazole recipients. Fidaxomicin treatment may therefore lower the C. difficile transmission risk by reducing excretion and environmental contamination. |
| spellingShingle | Davies, K Mawer, D Walker, AS Berry, C Planche, T Stanley, P Goldenberg, S Sandoe, J Wilcox, MH An analysis of C.difficile environmental contamination during and following treatment for C.difficile infection |
| title | An analysis of C.difficile environmental contamination during and following treatment for C.difficile infection |
| title_full | An analysis of C.difficile environmental contamination during and following treatment for C.difficile infection |
| title_fullStr | An analysis of C.difficile environmental contamination during and following treatment for C.difficile infection |
| title_full_unstemmed | An analysis of C.difficile environmental contamination during and following treatment for C.difficile infection |
| title_short | An analysis of C.difficile environmental contamination during and following treatment for C.difficile infection |
| title_sort | analysis of c difficile environmental contamination during and following treatment for c difficile infection |
| work_keys_str_mv | AT daviesk ananalysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT mawerd ananalysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT walkeras ananalysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT berryc ananalysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT planchet ananalysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT stanleyp ananalysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT goldenbergs ananalysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT sandoej ananalysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT wilcoxmh ananalysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT daviesk analysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT mawerd analysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT walkeras analysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT berryc analysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT planchet analysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT stanleyp analysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT goldenbergs analysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT sandoej analysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection AT wilcoxmh analysisofcdifficileenvironmentalcontaminationduringandfollowingtreatmentforcdifficileinfection |